Published in Cancer Weekly, October 7th, 1996
The results of the G3139 antisense compound were presented at the 12th International Roundtable on Nucleosides, Nucleotides and Their Biological Applications, held in San Diego, California, in September 1996.
The presentations, given by Dr. Lyle J. Arnold Jr., Genta, and other Genta scientists, featured results of recent preclinical (animal) studies which included anti-tumor activity of G3139 as monotherapy against breast, colon and ovarian cancers and corroboration of a previous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.